<DOC>
	<DOCNO>NCT00001766</DOCNO>
	<brief_summary>This study examine interaction various drug use treat HIV infection order design large study possible combination people continue high viral level despite combination therapy . HIV-infected patient 18 year age old viral load least 500 copies/mL ; receive 20 week protease inhibitor therapy , protease inhibitor combination therapy last 12 week ; never treat abacavir , amprenavir efavirenz enrol . All patient receive 600 milligram day efavirenz ( non-nucleoside reverse transcriptase inhibitor ) ; 300 mg twice daily abacavir ( nucleoside analog ) ; 1200 mg twice day amprenavir ( protease inhibitor ) . In addition drug , six patient receive 500 mg twice day ritonavir ( protease inhibitor ) ; six patient receive 200 mg twice day ritonavir ; 10 receive 1250 mg twice day nelfinavir ( protease inhibitor ) . Patients two ritonavir group ( 500-mg 200-mg dose group ) take abacavir amprenavir one week come clinic blood test measure drug level take morning pill 1/2 , 1 , 2 , 4 , 8 , 12 hour take medicine . They add ritonavir treatment regimen . After one week , return blood test . They add efavirenz regimen blood draw another 1 2 week . Patients nelfinavir group take abacavir , amprenavir nelfinavir one week blood sample describe ritonavir group . They add efavirenz regimen repeat blood test another 1 2 week . Participants see clinic follow-up wish continue participate regimen appear offer clinical benefit .</brief_summary>
	<brief_title>Drug Interactions Among Anti-HIV Agents</brief_title>
	<detailed_description>In study pharmacokinetic interaction , ( 1 ) effect ritonavir pharmacokinetics amprenavir ; ( 2 ) effect efavirenz pharmacokinetics amprenavir ritonavir , ( 3 ) effect efavirenz pharmacokinetics amprenavir nelfinavir examine . Twenty-two patient viral burden least 500 copies/mL combination therapy protease inhibitor least 20 week enrol receive open-label treatment , 6 abacavir 300 mg po BID , amprenavir 1200 mg po BID , ritonavir 200 mg po BID efavirenz 600 mg po QD , 6 abacavir 300 mg po BID , amprenavir 1200 mg po BID , ritonavir 500 mg po BID efavirenz 600 mg po QD , 10 abacavir 300 mg po BID , amprenavir 1200 mg po BID , nelfinavir 1250 mg po BID efavirenz 600 mg po QD . The group enrol sequentially : low-dose ritonavir combination group , full dose ritonavir combination group , nelfinavir combination group . Subjects see pre-entry , baseline ( Day 1 ) , thereafter study week 1 ( serial sampling ) , 2 ( serial sampling ) , 4 , 8 , 12 , 16 , 24 every 8 week one year . Patients discontinue current therapy without washout period begin dose . For group receive ritonavir , schedule : dose abacavir amprenavir , one-week , serial plasma sample perform baseline amprenavir level . Next ritonavir assign dose add ( full-dose , rapid dose escalation ) plasma sample repeat one week later ; finally , efavirenz 600 mg daily add plasma sample repeat 2 week begin combination . For nelfinavir group , schedule : dose nelfinavir , amprenavir , abacavir one week obtain serial plasma sampling , add efavirenz another week obtain serial plasma sample . Patients confirm increase viral burden one log great baseline end study participation . The safety antiviral activity combination also assess continue assess ; toxicity management outline protocol . This study remain open order continue provide drug subject complete original one-year study period wish continue medication appear , viral load , benefit .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>INCLUSION Adults ( great 18 year ) infect HIV1 . Plasma viral burden great 500 RNA copies/ml bDNA method screen visit receive protease inhibitor part combination therapy . Treatment protease inhibitor inhibitor ( ) precede 20 week protease inhibitor drug change dose interruption great 3 day recent 12 week . Laboratory value screen : hemoglobin great 9 g/dl ; granulocyte count great 900 cells/microL ; platelet count great 80,000 cells/microL ; AST ( SGOT ) less 151 U/L ; Creatine le 2 mg/dL . Willingness avoid become pregnant cause pregnancy use effective method include surgical sterilization barrier method condom and/or diaphragms . Hormonal method birth control acceptable unless barrier method also use drug interaction may render concentration subtherapeutic . Willing able provide write informed consent . Negative serum urine pregnancy test day enrollment . No intolerance ritonavir nelfinavir . EXCLUSION Treatment systemic corticosteroid great physiologic replacement dos , interleukin , interferon , radiation therapy cytotoxic chemotherapeutic agent within 30 day study drug administration anticipate need radiation chemotherapy treatment within next 48 week ( exception local treatment Kaposi 's sarcoma ) . Subjects suffer serious medical condition diabetes , congestive heart failure , cardiomyopathy , cardiac dysfunction , , opinion investigator , would compromise safety patient . Current anticipated therapy agent document activity HIV1 vitro ( stable maintenance dose foscarnet begin prior screen ) . Prior exposure abacavir , amprenavir efavirenz . Concomitant therapy entry corticosteroid replacement dos , chemotherapy , investigational agent . Active , untreated opportunistic infection major illness would , opinion investigator , increase risk adverse event might pose patient might render patient ill return study visit . Lymphoma diagnose within 5 year study enrollment . Significant substance abuse psychiatric illness might interfere assessment compliance . Refusal employ adequate mean birth control ( nonhormonal method ) ; efavirenz potentially teratofenic conception must avoid . Malabsorption gastrointestinal dysfunction , opinion investigator , might interfere drug absorption render patient unable take oral medication . History serious rash ( erythema multiforme StevensJohnson syndrome ) cause nevirapine delavirdine . Treatment phenobarbital , rifampin , rifabutin , midazolam , astemizole , cisapride , triazolam unless subject safely able discontinue drug ( ) prior receipt study medication . Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2003</verification_date>
	<keyword>Abacavir</keyword>
	<keyword>Salvage</keyword>
	<keyword>Drug Interaction</keyword>
	<keyword>Drug Levels</keyword>
	<keyword>Anti-Viral</keyword>
	<keyword>HIV</keyword>
</DOC>